Literature DB >> 24971917

Prognostic markers for the development of type 1 diabetes in first-degree relatives of diabetic patients.

Katarzyna Siewko1, Anna Popławska-Kita, Beata Telejko, Rafał Maciulewski, Anna Zielińska, Agnieszka Nikołajuk, Maria Górska, Małgorzata Szelachowska.   

Abstract

INTRODUCTION: The aim of this study was to evaluate beta-cell function and insulin resistance in relation to the occurrence of anti-islet antibodies in first degree relatives of patients with type 1 diabetes (T1D).
MATERIAL AND METHODS: The group studied consisted of 90 relatives and 60 healthy individuals without a family history of diabetes. An intravenous glucose tolerance test (IVGTT) was performed in all participants and the first phase insulin response index (FPIR) was calculated. Serum concentrations of GADA, IAA and IA-2A were measured by RIA. HOMA-IR and HOMA%B indices were calculated using a computer calculator from website.
RESULTS: At least one positive antibody was found in 28 relatives (31.1%) but in none of the controls. The most frequently detected antibodies were IAA (22.2%). The relatives of diabetic patients had significantly higher fasting insulin level (p), significantly lower FPIR index(p), as well as higher HOMA-IR (p) and lower HOMA%B (p) compared to the controls. A positive correlation between IAA concentration and HOMA-IR (r = 0.287, p < 0.005) and a negative correlation between IAA level and HOMA%B (r = -0.226, p < 0.05) were also shown.
CONCLUSIONS: Our results confirmed that more than 30% of the first-degree relatives of diabetic patients have positive markers of autoimmune beta-cell destruction. The study showed also that these individuals, in spite of normal glucose tolerance, have markedly decreased beta-cell secretory reserve and decreased sensitivity to insulin action, strongly suggesting an increased risk for developing diabetes later in life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24971917     DOI: 10.5603/EP.2014.0024

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  7 in total

1.  HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Authors:  Jamie L Felton; David Cuthbertson; Megan Warnock; Kuldeep Lohano; Farah Meah; John M Wentworth; Jay Sosenko; Carmella Evans-Molina
Journal:  Diabetologia       Date:  2021-10-12       Impact factor: 10.460

Review 2.  Environmental Factors and the Risk of Developing Type 1 Diabetes-Old Disease and New Data.

Authors:  Katarzyna Zorena; Małgorzata Michalska; Monika Kurpas; Marta Jaskulak; Anna Murawska; Saeid Rostami
Journal:  Biology (Basel)       Date:  2022-04-16

3.  Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Hang Xiang; Chao Yang; Tianyuan Xiang; Zheng Wang; Xin Ge; Fan Li; Yuehan Su; Haixu Chen; Xianyong Huang; Qiang Zeng
Journal:  Stem Cells Transl Med       Date:  2016-03-29       Impact factor: 6.940

4.  β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.

Authors:  Carmella Evans-Molina; Emily K Sims; Linda A DiMeglio; Heba M Ismail; Andrea K Steck; Jerry P Palmer; Jeffrey P Krischer; Susan Geyer; Ping Xu; Jay M Sosenko
Journal:  JCI Insight       Date:  2018-08-09

5.  MicroRNA-224 is Readily Detectable in Urine of Individuals with Diabetes Mellitus and is a Potential Indicator of Beta-Cell Demise.

Authors:  Siobhán Bacon; Britta Engelbrecht; Jasmin Schmid; Shona Pfeiffer; Ross Gallagher; Ailbhe McCarthy; Marie Burke; Caoimhín Concannon; Jochen H M Prehn; Maria M Byrne
Journal:  Genes (Basel)       Date:  2015-06-23       Impact factor: 4.096

6.  Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development.

Authors:  Katarzyna Siewko; Rafal Maciulewski; Anna Zielinska-Maciulewska; Anna Poplawska-Kita; Piotr Szumowski; Natalia Wawrusiewicz-Kurylonek; Danuta Lipinska; Robert Milewski; Maria Gorska; Adam Kretowski; Malgorzata Szelachowska
Journal:  Biomed Res Int       Date:  2019-10-20       Impact factor: 3.411

Review 7.  B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes.

Authors:  Jamie L Felton; Holly Conway; Rachel H Bonami
Journal:  Biomedicines       Date:  2021-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.